|Sativex||diabetes,neuropathy in humans via placebo trial (n=30)||Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor.||Oct 2009|
|Neutral There was significant improvement in pain scores in both groups, but mean change between groups was not significant. There were no significant differences in secondary outcome measures. Patients with depression had significantly greater baseline pain scores that improved regardless of intervention.|
|Sativex,CBD||drug potentiator,metabolism in humans via trial (n=9)||Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration.||Jan 2011|
|Decreases in mean 11-OH-THC Cmax and AUC0->10.5 hafter only high-dose Sativex might indicate that CBD does not interact with THC at lower doses (5 mg), but could alter THC metabolism at higher CBD doses (>=15 mg)|
|Sativex||safety in humans via placebo trial (n=17)||Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study.||Jan 2009|
|Cannabinoid treatment did not induce psychopathology and did not impair cognition in cannabis-naive patients with MS.|
|Sativex||adhd in humans via placebo trial (n=30)||Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial.||Aug 2017|
Ingestion Method: Sativex Oromucosal Spray|
For the primary outcome, no significant difference was found in the ITT analysis although the overall pattern of scores was such that the active group usually had scores that were better than the placebo group (Est=-0.17, 95%CI-0.40 to 0.07, p=0.16, n=15/11 active/placebo). For secondary outcomes Sativex was associated with a nominally significant improvement in hyperactivity/impulsivity (p=0.03) and a cognitive measure of inhibition (p=0.05), and a trend towards improvement for inattention (p=0.10) and EL (p=0.11). Per-protocol effects were higher.
|Sativex||cud in humans via placebo trial (n=128)||Nabiximols for the Treatment of Cannabis Dependence: A Randomized Clinical Trial.||Jul 2019|
|This study demonstrates that cannabinoid agonist treatment, in this case using nabiximols, in combination with psychosocial interventions is a safe approach for reducing cannabis use among individuals with cannabis dependence who are seeking treatment.|
|Sativex||tourettes in humans via case study (n=1)||Severe motor and vocal tics controlled with Sativex||Dec 2016|
|Both subjective and objective measures demonstrated marked improvement in the frequency and severity of motor and vocal tics post-treatment. There was good interrater reliability of results.|
|Sativex||tourettes in humans via case study (n=1)||Significant Tic Reduction in An Otherwise Treatment-Resistant Patient with Gilles de la Tourette Syndrome Following Treatment with Nabiximols||Apr 2017|
Ingestion Method: 1 puff/day increased to 3/day|
Treatment with nabiximols resulted in major improvements of both tics and premonitory urges, but also global impairment and health-related quality of life according to all used measurements without causing relevant adverse effects. Our results provide further evidence that treatment with nabiximols may be effective in the treatment of patients with TS.